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Abstract
Background: Coffee contains several compounds that have the potential to influence breast cancer risk and survival.
However, epidemiologic data on the relation between coffee compounds and breast cancer survival are sparse and
inconsistent.
Results: We show that coffee component HHQ has significant apoptotic effect on MDA-MB-231 and MCF-7 cells
in vitro, and that ROS generation, change in mitochondrial membrane permeability, upregulation of Bax and
Caspase-8 as well as down regulation of PGK1 and PKM2 expression may be important apoptosis-inducing
mechanisms. The results suggest that PPARg ligands may serve as potential therapeutic agents for breast cancer
therapy. HHQ was also validated as a ligand for PPARg by docking procedure.
Conclusion: This is the first report on the anti-breast cancer (in vitro) activity of HHQ.
Background
Breast cancer is the fifth most common cancer globally
and accounts for the highest morbidity and mortality. It is
the second highest occurring cancer in women and one of
the leading causes of death [1]. Although anti-estrogens
have provided an effective endocrine therapy, a significant
proportion of patients have acquired resistance to these
drugs. Hence, there is a requirement for alternative thera-
peutics to treat breast cancer. Since, cancer cells modify
several pathways to achieve continuous progression and
survival, and undergo metabolic alterations, it is important
that multiple target strategies are used to achieve effective
treatment. Several drugs that inhibit metabolism of cancer
cells by targeting a variety of molecules (including
enzymes) directly or indirectly are currently under
clinical trials, hence it is important to screen drugs with
a potential to target critical molecules involved in meta-
bolic transformation [2].
PPARg receptor is a member of the nuclear receptor
superfamily which upon ligand activation undergoes
heterodimerization with retinoic acid-like receptor (RXR)
and is translocated to the nucleus where it recognizes a
specific sequence - the peroxisome proliferator response
element (PPRE) located within promoters of target genes,
and acts as a transcription regulator for genes involved in
proliferation, cell differentiation, apoptosis, angiogenesis,
inflammation, organogenesis, and lipid and carbohydrate
metabolism and energy homeostasis [3-5]. Two isoforms
of PPARg have been identified (PPARg 1 and PPARg 2),
with a wide tissue distribution among various animal
species [6]. PPARg are expressed in a variety of tumor
cells and PPARg agonists e.g Thiazolidinediones (TZDs),
and tyrosine based agonists show cytostatic and cytotoxic
activity against tumor cells in vitro and in vivo brought
about by regulating proteins involved in growth regulatory
pathways and cell cycle [7]. TZDs are also reported to
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induce G0/G1 arrest and apoptosis of malignant cells by
upregulation of the tumor suppressor p53, and control of
DNA repair systems and apoptosis [8]. However, the exact
mechanism of action and the genes regulated by PPARg
and biological functions of this transcription factor are not
known and need elucidation.
Also, due to high levels of toxicity associated with TZDs
(e.g. - troglitazone (Rezulin), rosiglitazone (Avandia), and
pioglitazone (Actos)), and their recent withdrawal in
several countries, there is a need to search for newer
PPAR drugs that exhibit better efficacy but lesser toxicity.
Phytochemicals in dietary components are increasingly
being used as nutritional supplements in treatment of
diseases. Due to the plant origin of these supplements they
are considered safe for human consumption [9]. Present
data reveal that healthy dietary molecules have a
pleiotropic role and are able to change cell metabolism
from anabolism to catabolism, modulate energy homeosta-
sis and down regulate inflammation by interacting with
enzymes, nuclear receptors and transcriptional factors [10].
Towards this end developing and positioning known
phytochemicals that bind and activate PPARg with more
efficacy and safety, while promoting health benefits has
become an absolute necessity. Also, it is important to
identify the dietary molecules able to influence the course
of the disease, their targets in the cell, and the molecular
mechanisms involved.
Coffee is one of the most widely consumed beverages in
the world. The health-promoting properties of coffee are
often attributed to its rich phytochemistry, including
caffeine, chlorogenic acid, caffeic acid, hydroxyl hydroqui-
none (HHQ), etc. More recently, coffee consumption has
been associated with reductions in the risk of several
chronic diseases, including type 2 diabetes mellitus,
Parkinson’s disease and hepatocellular disease [11-13].
The association between coffee intake and breast cancer
risk is biologically plausible because of its complex
make-up of chemicals, e.g., caffeine and polyphenolic
compounds such as flavonoids and lignans [14-16].
Among them, the relationship between coffee drinking
and breast cancer risk holds great interest. Recent meta-
analyses demonstrate inverse associations between coffee
intake and the risk of colon, liver, breast, and endometrial
cancer [17-20]. Also, a high daily intake of coffee has
recently been reported to be associated with a statistically
significant decrease in ER-negative breast (ER - Estrogen
Responsive) cancer among postmenopausal women [21].
A number of previous epidemiologic studies have esti-
mated the association between coffee consumption and
breast cancer risk. However, the results are inconsistent
[22]. Nevertheless, several reports in literature suggest that
coffee consumption reduces the risk of cancer, but the
molecular mechanisms of its chemopreventive effects
remain unknown. Moreover, the interpretation of
these data has often been limited to the role that caffeine
plays [23,24].
HHQ is a natural constituent of coffee accounting for
main dry matter constituent in roasted beans. Studies
exploring the effects of this bioactive compound on
mammalian cells are limited. HHQ was observed to dock
and form hydrogen bonds with PDB ID - 2PRG (PDB 3-D
crystal structure of the Ligand-binding domain of the
human peroxisome proliferator activated receptor gamma
solved in complexation with Rosiglitazone, the PPAR
gamma agonist/ligand). The initial purpose of our investi-
gation is to determine whether HHQ alters the cell
viability in estrogen dependent human breast cancer
(MCF-7) and estrogen independent (MDA-MB-231) cells
as a model system. HHQ was observed to decrease cell
viability and colony formation in a dose-responsive
manner and ROS was found to significantly increase in
HHQ treated cells in a dose-dependent manner in
both the cell lines. We examined the involvement of
ROS signaling components (ROS levels and membrane
potential) and demonstrated that the selective killing of
cancer cells is mediated by induction of oxidative stress
that leads to apoptosis. These findings were complemen-
ted by the finding that caspase-8 is upregulated. Since
glucose utilization provides a constant energy supply,
as well as precursors for de novo macromolecular
biosynthesis, including DNA, RNA, fatty acids and amino
acids that are essential for cell growth and proliferation,
we further investigated the effect of HHQ on two key
glycolytic genes PGK1 and PKM2 (at the ATP generation
step) and observed that both the genes are repressed in a
dose-dependent manner. These data suggest on the
apoptotic and anti-cancer properties of HHQ via PPARg.
Further investigations on these could possibly help us in
understanding the molecular mechanisms by which
PPARg regulates disease targets specifically in breast
cancer and the use of HHQ in breast cancer therapeutics.
Results and discussion
Understanding the molecular pathways that link tumor
biology to the staggering array of pathologies and genes is
of paramount scientific and medical importance. Though,
the complexity of the underlying biochemical and molecu-
lar mechanisms of breast cancer make metabolic repro-
gramming and transformation in breast cancer unclear,
many dietary compounds have been identified as potential
chemopreventive agents. PPARg is an interesting target for
cancer therapy as its expression is elevated in tumors and
also because PPARg activation is reported to result in
decreased cell proliferation, decreased G0/G1 to S phase
progression, apoptosis and increased terminal differentia-
tion [25-27]. Also, imbalances in expression of target
genes forms the core of metabolic syndrome and cancer
regulation through atherogenic metabolic triad/lipid triad
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metabolism modulation by PPARs [28]. Concurrently,
increased levels of glycolytic proteins are observed in
plasmas of women with breast cancer as a result of
upregulation of glycolysis pathway [29].
In this paper, we for the first time report on the use of
coffee component HHQ as a potential ligand for PPARg
and its role in induction of apoptosis in breast cancer cells
by delineating the glycolytic pathway gene regulation by
PPARg activation.
Docking
The three-dimensional protein structures can be used to
understand ligand binding and to rationally design novel
ligands as prospective drug compounds. PPAR agonists
typically possess a small polar region and a hydrophobic
region that form hydrogen bonds and hydrophobic
interactions, respectively, within the ligand binding
domain. Several crystal structures of PPARg in com-
plexation with their ligands are available in the protein
data bank (PDB). Here, we used the PDB crystal struc-
ture 2PRG (PPARg with ligand Rosiglitazone) for struc-
ture-based identification of HHQ as a potential ligand
for PPARg in breast cancer therapeutics. We also com-
pared the ligand binding properties of the two com-
pounds Rosiglitazone (the known ligand) and HHQ (the
proposed novel ligand). The rerank scores for the Rosi-
glitazone and HHQ were found to be -122.433 and
-33.3562, respectively. The hydrogen bond energy values
were -5.487 kcal/mol, and -9.460 kcal/mol for Rosiglita-
zone and HHQ. Rosiglitazone (the ligand in the crystal
structure 2PRG) forms 3 hydrogen bonds with the
2PRG (Gln286, His449, Ser289) and HHQ forms
5 hydrogen bonds with 2PRG (Gln286, His449, Tyr473,
Ser289, His323). Hydrogen bonding of the ligand to
Tyr473 is reported to be the key to the stabilization of
the AF-2 region and it has also been shown that [30]
agonistic activity of ligands disappears when Tyr473 is
mutated. The importance of His323 and His449 has also
been reported [31,32]. Our results show that both the
ligands have hydrogen bond interactions with key resi-
dues - Tyr473 and His 449, thereby providing specificity
of interaction that is a fundamental aspect of molecular
recognition. The active site residues that interact with
HHQ are shown in Table 1 and the hydrogen bonds
between each compound and the 2PRG active site are
shown in Figure 1.
HHQ inhibits cell proliferation and clonogenic survival
To investigate the potential cell growth inhibition of HHQ,
we first examined the effect of HHQ on cell proliferation
and clonogenic survival in human breast adenocarcino-
mas. For this we chose two breast adenocarcinoma cell
lines, MDA-MB-231 (estrogen independent) and MCF-7
(estrogen dependent). MDA-MB-231 and MCF-7 were
cultured in the control medium for 24 h, followed by 48 h
treatment with different concentrations of HHQ for cyto-
toxic and anti-proliferative studies. HHQ led to decrease
in relative density of viable cells as detected by MTT dye
reduction assay. A dose-effect relationship was observed as
shown in Figure 2. The IC-50 value for MDA-MB-231 and
MCF-7 were found to be 25 μM and 50 μM, respectively.
We proceeded with 12.5 μM and 25 μM of HHQ to inves-
tigate the comparable effects of same concentration on
both the cell lines. At 12.5 μM the relative viability
in MDA-MB-231 and MCF-7 was 58.2% and 76.3%,
respectively, whereas at 25 μM the relative viability in
MDA-MB-231 and MCF-7 was 50% and 60.7%, respec-
tively. As morphological analyses depict the health of
a cell, we next examined the cells for any altered morphol-
ogy on treatment with HHQ. Cells cultured in the
presence of HHQ (12.5 μM and 25 μM) show significant
morphological changes and were found to be reduced in
cell mass as well as number as compared to control. Also,
HHQ treatment induced detachment and rounding in
breast cancer cells as shown by phase contrast images in
both the cell lines (Figure 3 (12.5 μM and 25 μM)).
Furthermore, to examine the antitumor activity of HHQ
on colony forming potential in breast cancer cells we
performed clonogenic assay. This assay is an in vitro assay
based on the ability of a single cell to proliferate and
differentiate into colonies in response to various insults.
HHQ severely affected the colony forming potential of
human breast cancer cells - MDA-MB-231 and MCF-7.
As shown in Figure 4A and 4B clonogenicity of both the
breast cancer lines were found to be significantly reduced
in a concentration-dependent manner after exposure
to HHQ.
HHQ induces intracellular ROS generation and cytotoxicity
Reactive oxygen species (ROS) is a universal entity med-
iating apoptosis [33]. ROS act as a secondary messenger
in cell signaling and are essential for various biological
processes in normal cells. Disturbances in redox balance
Table 1 Docking results for HHQ and Rosiglitazone.








HHQ -9.46033 5 Gln286, His449, Tyr473, Ser289, His323 -33.3562
Rosiglitazone -5.48771 3 Gln286, His449, Ser289 -122.433
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relate to human pathogenesis including cancers. ROS
are constantly generated and eliminated in the biological
system, and play important roles in a variety of normal
biochemical functions and abnormal pathological
processes. Growing evidence suggests that cancer cells
exhibit increased intrinsic ROS stress, due in part to
oncogenic stimulation, increased metabolic activity, and
mitochondrial malfunction. Since ROS are chemically
active and can inflict severe cellular damage, the very
fact that cancer cells are under increased intrinsic ROS
stress may also provide a unique opportunity to kill the
malignant cells based on their vulnerability to further
ROS insults caused by exogenous agents [34]. HHQ is
earlier reported to generate reactive oxygen species
(ROS) by autoxidation [35]. Therefore, to get further
insights to HHQ induced cytotoxicity in breast cancer
cells; we examined the intracellular ROS generation. As
shown in Figure 5, intracellular ROS formation was
found to be significantly increased in HHQ treated cells
as compared to control cells in a dose-dependent man-
ner. The effective enhancement of ROS production by
HHQ correlates to its cytotoxicity nature. Since the
mitochondrial respiratory chain (electron transport
chain) is a major source of ROS generation in the cells,
the vulnerability of the mitochondrial DNA to ROS
mediated damage has been suggested to be a mechan-
ism to amplify ROS stress in cancer cells [36]. One
major effect is to generate increased intracellular ROS
causing loss of outer mitochondrial membrane perme-
ability and induction of apoptosis [37,38]. Another pos-
sible mechanism by which cancer cells generate
increased amounts of ROS may involve malfunction of
the mitochondrial respiratory chain. The fact that cancer
cells exhibit an increased dependency on glycolysis to
meet their ATP need (the Warburg effect) may reflect
an inefficient ATP generation in mitochondria, or
Figure 1 HHQ docked in the ligand binding domain of PPARg protein crystal structure for PDB solved in conjunction with
Rosiglitazone (PDBID: 2PRG). [A] Represents hydrogen bonds (in black dotted line) observed for Rosiglitazone (in red) with the active site
residues in the ligand binding domain of PPARg (2PRG). [B] Represents hydrogen bonds (in black dotted line) observed for HHQ (in yellow) with
the active site residues in the ligand binding domain of 2PRG. [C] Represents superposition of the best conformation of Rosiglitazone (in red)
and HHQ (in yellow) in the ligand binding domain of 2PRG.
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Figure 2 Growth curve inhibition as assessed by MTT assay in human breast cancer cells (MDA-MB-231 (blue line) and MCF-7
(grey line)). The breast cancer cells were exposed to different doses of HHQ for 48 h at 37 °C. The cell viability in breast cancer cells decreased
in dose-dependent fashion. The IC-50 value for MDA-MB-231 and MCF-7 were observed to be 25 μM and 50 μM, respectively. Data are
representative of three independent experiments done in triplicates and expressed as mean ± S.E.M. *p < 0.005 represents statistical significant
difference between control and HHQ test groups.
Figure 3 Phase contrast images of human breast cancer cells (MDA-MB-231 and MCF-7). The breast cancer cells were exposed to 12.5 µM
and 25 µM concentration of HHQ for 48 h at 37 °C. HHQ treated groups did not retain their normal morphology. HHQ induced cell rounding
and detachment in breast cancer cells.
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“respiration injury” [39]. A correlation between mtDNA
mutations and increased ROS contents in primary
leukemia cells isolated from patients has been shown
[40]. Because the mitochondrial respiratory chain is the
major site of ROS generation due to electron transfer,
malfunction of the mitochondrial respiratory chain asso-
ciated with mtDNA mutations is likely to result in more
free radical production due to increased “leakage” in
mitochondrial membrane.
HHQ induces mitochondrial dysfunctioning
Mitochondria are central players in the determination of
cell life and death. Their main physiological function is
energy production by the oxidative phosphorylation
pathway. This process not only involves production of cell
energy currency, ATP but also increases the production of
reactive oxygen species (ROS) as by-products of aerobic
metabolism. Mitochondria are also the main regulators of
apoptotic cell death by mediating extrinsic and intrinsic
Figure 4 The inhibitory effects of HHQ on colony formation in human breast cancer cells (MDA-MB-231 and MCF-7) as evaluated
by clonogenic assay. The breast cancer cells were exposed to 12.5 µM and 25 µM concentration of HHQ for 48 h at 37 °C. [A] Representative
plates; [B] graph of the number of colonies formed (the result of three independent experiments, expressed as mean ± SEM). Decrease in
number of colonies in HHQ treated groups were statistically significant (*P<0.05).
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Figure 5 HHQ induced intracellular ROS production in human breast cancer cells, MDA-MB-231 [A] and MCF-7 [C]. The breast cancer
cells were treated with 12.5 μM and 25 μM of HHQ for 48 h at 37 °C, intracellular ROS was detected by a fluorescent microscope. Quantitation of the
ROS signals in MDA-MB-231 and MCF-7 is shown in [B] and [D], respectively. Significant increase in ROS level was observed in HHQ treated cells. Data
are representative of three independent experiments done in triplicates and expressed as mean ± S.E.M. Increase in ROS generation in HHQ treated
groups with 12.5 μM and 25 μM were statistically significant (*P<0.05).
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apoptotic pathways. Oxidative stress may cause oxidative
damage to various cellular components and may lead to
lipid peroxidation, protein oxidation, mitochondrial DNA
mutations, initiation of apoptosis cascade by decrease in
mitochondrial membrane potential and release of apopto-
genic factor cytochrome c into the cytosol [41]. Thus, the
oxidative damage and the associated mitochondrial
dysfunction may lead to energy depletion, accumulation of
cytotoxic mediators, apoptosis and ultimately cell death.
Therefore to investigate the effect of HHQ induced oxida-
tive stress on mitochondria and apoptosis cascade initia-
tion, we undertook mitochondrial membrane potential
analysis using potential sensitive, cationic dye JC1. This dye
exhibits potential-dependent accumulation in mitochon-
dria, indicated by a fluorescence emission shift from green
(525 nm) to red (590 nm). Consequently, live cells have
higher red/green intensity ratio as compared to cells under-
going apoptosis. As shown in Figure 6, we observed that
the breast cancer cells when treated with HHQ show loss
of mitochondria membrane potential (MMP) in a dose-
dependent manner. This decrease in MMP at 25 μM of
HHQ was significant in both the cell lines. Furthermore,
we found that the level of pro-apoptotic protein Bax,
significantly increased in a concentration-dependent
manner in both the breast cancer cells (Figure 7). The
expression levels of Bax correlates with the MMP loss in
breast cancer cells on treatment with HHQ. This protein is
involved in the mitochondrial apoptotic signaling pathway.
The activation of the proapoptotic Bcl-2 family member
Bax, induces permeabilization of the mitochondrial outer
membrane and release of cytochrome c leading to caspase
dependent apoptosis [42,43]. Together, these data corrobo-
rate with our previous results and demonstrate that there
is disruption in mitochondrial potential, permeability and
functioning upon PPARg activation by HHQ.
Induction of caspase dependent apoptosis by HHQ
Caspase-8 activation is one of the early events leading to
apoptosis. PPAR synthetic ligands are known to activate
intrinsic and extrinsic apoptotic cascade [44,45]. In order
to understand the mechanism of cell death, we hypothe-
sized that PPARg ligand HHQ may initiate apoptosis
cascade via PPARg dependent pathway. To examine the
above hypothesis we undertook the expression analysis of
apoptotic protein, caspase-8. Interestingly, we observed
that on treatment with HHQ the level of procaspase-8
decreases significantly in both the cancer cells. This
demonstrates that caspase-8 proenzyme is being cleaved
to active caspase-8 fragments in a dose-dependent manner
(Figure 8). Concurrent increase in proapototic protein
Bax, loss of mitochondrial membrane potential and activa-
tion of caspase-8 demonstrate PPARg dependent apoptotic
cascade activation by HHQ.
PPARg dependent modulation of glycolytic enzymes
In 1930, Otto Warburg discovered the unknown link
between highly proliferative nature of cancer cells and
glycolysis. The phenomenon involved was described as
the “Warburg Effect” which is characterized by increased
glucose uptake and dependence on glycolysis for ATP
production even in the presence of oxygen source. The
glycolytic rate of rapidly proliferating tumor cells was
Figure 6 HHQ induced loss in mitochondrial membrane potential (MMP) in human breast cancer cells (MDA-MB-231 and MCF-7).
The breast cancer cells were treated with 12.5 μM and 25 μM of HHQ for 48 h at 37 °C and then immunostained for JC1. HHQ treated cells
showed loss of MMP comparable to that of the control cells. Data are representative of three independent experiments done in triplicates and
expressed as mean ± S.E.M. *p < 0.005 represents statistical significant difference between control and HHQ test groups.
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found to be 200 times higher than those of their normal
tissues of origin. Altenberg and Greulich (2004) found
over expression of glycolytic genes in 24 different types
of cancer including breast cancer. Two such glycolytic
genes are phosphoglycerate kinase 1 (PGK1) and tumor
specific pyruvate kinase muscle 2 (PKM2) [46,47]. PGK1
and PKM2 catalyze the sixth and ninth step, respectively,
in the glycolysis pathway generating two ATPs each.
PGK1 also functions as a polymerase alpha cofactor
protein (primer recognition protein) and is involved in
DNA synthesis. PKM2 on the other hand is also a meta-
bolic regulator and is also reported to be involved in
channelization of glucose carbons to biosynthetic
processes and hence control glycolysis. Hence, down
regulating these enzymes would not only starve the cells
for ATP but also lead to biosynthetic metabolite starva-
tions, as they are important for tumor cell proliferation
and survival. Earlier, we reported that both phosphogly-
cerate kinase 1 (PGK1) and pyruvate kinase M2 (PKM2)
are repressed by PPARg in the same two breast cancer
cell lines MDA-MB-231 and MCF-7. Further analysis
suggested that this repression leads to decrease in ATP
levels and apoptosis [48]. Here, we hypothesized (based
on docking results) that HHQ can modulate the expres-
sion of PGK1 and PKM2 via PPARg dependent pathway.
Therefore, to test this hypothesis, we undertook expres-
sion analysis of these metabolic enzymes. We observed
that the expression of glycolytic genes, PGK1 and PKM2
was significantly reduced in both the breast cancer cells
on treatment with HHQ in dose-dependent manner,
Figure 9, 10. Further, to confirm the repression of glyco-
lytic genes, PGK1 and PKM2 through HHQ induced
PPARg activation, we utilized GW9662, an irreversible
PPARg antagonist which acts by binding to the human
ligand-binding domain (region E/F). As shown in Figure 11,
no significant repression of PGK1 and PKM2 was seen on
pre-treating the breast cancer cells with GW9662 (10 μM,
4h at 37 °C) followed by HHQ (12.5 μM and 25 μM, 48 h
at 37 °C). GW9662 showed no effect of HHQ on expres-
sion of PGK1 and PKM2, thereby suggesting that the
activation of PPARg is required for repression of these
enzymes. Conversely, these data suggests that HHQ
Figure 7 Expression analyses of pro-apoptotic protein Bax in response to HHQ treatment in human breast cancer cells (MDA-MB-231
and MCF-7). The breast cancer cells were treated with 12.5 μM and 25 μM of HHQ for 48 h at 37 °C. Representative western blot hybridization
signals of Bax for MDA-MB-231 [A] and MCF-7 [B] and the quantitation of the signals is shown in [C] and [D], respectively. Significant increase in
Bax expression was observed in HHQ treated cells. Data are presented as mean ± SEM of three independent experiments. *p< 0.005 represents
statistical significant difference between control and HHQ test groups.
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represses the expression of glycolytic enzymes via PPARg
dependent pathway. Down regulation of PGK1 and
PKM2 decreases ATP production in the cytoplasm and
mitochondria, initiating apoptosis and suppressing cancer
metabolism. ATP depletion, used in combination with
chemotherapy and/or radiation, has a variety of effects on
cancer cells including inducing apoptosis in multi-drug
resistant cells and decreasing tumor promotion. Cellular
ATP level has been reported as an important determinant
of cell death [49]. Though the exact mechanisms of these
effects have not been fully elucidated, these investigations
suggest on the role of HHQ as an anti-cancer agent. How-
ever, further work is required to establish the exact nature
and behavior of this molecule in conjunction with other
coffee components and to determine its relevance to the
biological role of PPARg breast cancer progression and
therapeutics.
Conclusion
Our results have established previously unknown novel
cross-link between HHQ, PPARg, ROS and glycolysis;
thereby adding a new dimension to therapeutic potential
of PPARg ligands. Although the exact mechanism remains
unclear and further studies are still needed to clarify the
potential role and molecular basis of action of PPARg in
breast carcinogenesis, our investigation open a new direc-
tion for development HHQ in breast cancer treatment.
Further investigations on these could possibly help us in
understanding the molecular mechanisms by which
PPARg regulates disease targets specifically in breast can-
cer and the use of its ligands in breast cancer therapeutics.
Despite several advancements that have been made on the
subject, there is still much to be clarified regarding PPARg
signaling in breast cancer and several important questions
remain unanswered. Many intriguing avenues of PPARg
research have been opened and hold the potential to ulti-
mately lead to newer classes of more selective molecules.
Materials and methods
Docking of HHQ into PPARg structure
Docking studies were carried out using MolDock™
(Molegro virtual docker) which is based on a new heuristic
Figure 8 Expression analyses of proenzyme caspase-8 in response to HHQ treatment in human breast cancer cells (MDA-MB-231 and
MCF-7). The breast cancer cells were treated with 12.5 μM and 25 μM of HHQ for 48 h at 37 °C. Representative western blot hybridization
signals for proenzyme caspase-8 for MDA-MB-231 [A] and MCF-7 [B] and the quantitation of the signals are shown in [C] and [D], respectively.
Significant decrease in expression of proenzyme caspase-8 was observed in HHQ treated cells. Data are presented as mean ± SEM of three
independent experiments. *p< 0.005 represents statistically difference between control and HHQ test groups.
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search algorithm that combines differential evolution with
a cavity prediction algorithm (Thomsen & Christensen,
2006). The PDB file for the crystal structure of PPARg
(PDB ID - 2PRG) was downloaded from http://www.rcsb.
org and transferred into the workspace keeping the orien-
tation as a control. The energy between the existing ligand
and protein was subsequently minimized. Both protein and
ligands (Rosiglitazone and HHQ) were optimized in the
workspace for docking by the addition of hydrogens. All
structural water molecules were removed from the protein
molecules using protein preparation wizard. Binding sites
in the electrostatic surface of the protein was identified
using the grid based cavity prediction algorithm. A total of
five cavities were detected and the prepositioned ligand in
the active site cavity was identified and the docking was
constrained to the predicted active site cavity. MolDock™
scoring function is used for evaluating the energy between
the ligand and the protein target. Grid resolution, number
of runs, population size, maximum iterations, scaling
factor, and cross over rate were set as 0.30 Å, 10, 50, 2000,
0.5, 0.9, respectively, for each run. Multiple poses
were returned for each run with the RMSD threshold set
Figure 9 Expression analyses of glycolytic enzyme phosphoglycerate kinase 1 (PGK1) in response to HHQ treatment in human breast
cancer cells, MDA-MB-231 and MCF-7. The breast cancer cells were treated with 12.5 μM and 25 μM of HHQ for 48 h at 37 °C. Representative
western blot hybridization signals for PGK1 [A] and the quantitation of the signals is shown in [B]. Immunofluorescent detection of PGK1 is
shown in [C] and the relative intensity measurement of immunofluorescence is shown in [D]. Significant decrease in PGK1 expression was
observed in HHQ treated cells. Data are representative of three independent experiments done in triplicates and expressed as mean ± S.E.M.
‘’*’’ represents the statistical significant (p<0.05) difference between control and HHQ treated groups.
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to 1.00 Å. The pose with the highest rerank score was
retained in the workspace for detailed evaluation of the
ligand binding at the active site cavity. MVD was installed
in Windows vista operating system on an Intel Core 2.
Reagents
Dulbecco’s modified eagle’s medium (1000 mg/L glucose,
L-glutamine and sodium bicarbonate), Fetal bovine
serum, HHQ, GW9662 and crystal violet were purchased
from Sigma-Aldrich (St Louis, MO, USA). Penicillin-
Streptomycin-Neomycin antibiotic mixture, Hoechst
33258 and the Image-iTTM LIVE Green Reactive Oxygen
Species (ROS) detection reagents were procured from
Invitrogen (Eugene, OR, USA) and JC-1dye from Biotium
(Hayword, CA, USA). Sodium chloride, Tris base, potas-
sium chloride, sodium di hydrogen phosphate, glycine and
sodium phosphate di basic were purchased from Wako
Pure Chemical Industries (Osaka, Japan).
Cell culture and treatments
The human breast adenocarcinoma cell lines MCF-7 and
MDA-MB-231 were purchased from the American Type
Culture Collection (ATCC; Manassas, VA, USA). The car-
cinoma cultures were maintained in Dulbecco’s modified
eagle’s medium supplemented with 10% fetal bovine
serum and PNS antibiotic mixture 100 ng/ml at 37 °C and
5% CO2/95% O2. Cultures at about 50% confluency were
treated with 12.5 µM and 25 µM of HHQ concentration
Figure 10 Expression analyses of glycolytic enzyme pyruvate kinase-muscle 2 (PKM2) in response to HHQ treatment in human breast
cancer cell, MDA-MB-231 and MCF-7. The breast cancer cells were treated with 12.5 μM and 25 μM of HHQ for 48 h at 37 °C. Representative
western blot hybridization signals for PKM2 [A] and the quantitation of the signals is shown in [B]. Immunofluorescent detection of PKM2 is
shown in [C] and the relative intensity measurement of immunofluorescence is shown in [D]. Significant decrease in PKM2 expression was
observed in HHQ treated cells. Data are representative of three independent experiments done in triplicates and expressed as mean ± S.E.M. ‘’*’’
represents the statistical significant (p<0.05) difference between control and HHQ treated groups.
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Figure 11 PPARg dependent repression of glycolytic enzymes PGK1 and PKM2 by HHQ in human breast cancer cells, MDA-MB-231
and MCF-7. The breast cancer cells were pre-treated with a potent PPARg antagonist, GW9962 (10 μM) for 4 h at 37 °C, followed by treatment
with 12.5 μM and 25 μM of HHQ for 48 h at 37 °C. Representative western blot hybridization signals for PGK1 [A] and PKM2 [B] for both the
breast cancer cell lines and the quantitation of the signals is shown in [C] and [D], respectively. GW9662 showed no effect of HHQ on
expression of PGK1 and PKM2, thereby suggesting that the activation of PPARg is required for repression of these enzymes. Data are
representative of three independent experiments and expressed as mean ± S.E.M.
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for 48 h at 37 °C and for PPARg activity inhibition studies,
the breast cancer cells were pre-treated with GW9662
(10 μM, 4h at 37 °C) followed by HHQ (12.5 μM and
25 μM, 48 h at 37 °C) and harvested for further use.
Cell proliferation assay and morphological study
HHQ was tested for its anti-proliferative activity on MDA-
MB-231 and MCF-7 cells using the 3-(4, 5-dimethylthiazol-
2-yl)-2, 5-diphenyltetrazolium bromides (MTT) test
(Roche, Mannheim, Germany) following manufacturer’s
instructions. The MTT metabolic activity is a colorimetric
cell proliferation assay that identifies living cells, and is
based on the cellular conversion of a tetrazolium salt into
insoluble formazan, which can be quantified by spectropho-
tometry. 5 × 103 cells/ well were plated in 96-well plates
and grown for 24 h. The cells were then exposed to varying
concentrations of HHQ for 48 h to find the half maximal
inhibitory concentration (IC50) values. The intensity of the
reduced dye that corresponds to the viable cells was mea-
sured at reference wavelength of 570 nm by Thermo Scien-
tific Varioskan Flash Multimode Reader. Morphological
changes in breast cancer cells treated with 12.5 µM and
25 µM of HHQ concentration for 48 h were examined
by phase contrast microscopy. All experiments were
performed in triplicates, and the relative cell viability (%)
was expressed as a percentage relative to the untreated
control cells.
Clonogenic assay
Colony formation potential of human breast cancer cells
on exposure to HHQ was assessed by clonogenic assay.
Clonogenic assay is a cell survival assay based on the abil-
ity of a single cell to grow into a colony. To determine
long-term effects, breast cancer cells were treated with
12.5 µM and 25 µM of HHQ concentration for 48 h. At
the end of treatment the breast cancer cells were then
plated at a concentration of 100 cells/well in a new 6-well
plate. The cells were allowed to grow for 14 days to form
colonies. Fresh medium was replaced every third day. The
colonies were washed with PBS and fixed in pre-chilled
methanol: acetone mixture (1:1) for 10 min at room
temperature. The colonies were then stained with crystal
violet dye (0.5% in water) at room temperature for over-
night. Cells were washed with water and plates were
photographed with image scanner (EPSON GT-1500).
Quantitative analysis of the total number of colonies was
performed with Image J software (National Institutes of
Health).
Detection of reactive oxygen species
The reactive oxygen species were detected by fluorescent
staining using the Image-iTTM LIVE Green Reactive Oxy-
gen Species (ROS) Detection Kit (Molecular Probes Inc,
USA). The assay is based on a nonfluorescent and cell
permeable 5-(and-6)-carboxy-2’,7’-dichlorodihydrofluores-
cein diacetate (carboxy-H2DCFDA). The carboxy-
H2DCFDA permeates the live cells and is deacetylated by
intracellular esterases. The reduced fluorescein compound
is oxidized by the cellular ROS and emits bright green
fluorescence with excitation/ emission maxima of 495/529
nm. The cells were grown on glass cover slips placed in
12-well plate and were treated with 12.5 µM and 25 µM
concentration of HHQ for 48 h. Subsequently, cells were
fixed and then stained for ROS by following manufac-
turer’s instructions. The images were analyzed with Axio-
Vision software (version 4.4, Carl Zeiss).
Assessment of mitochondrial membrane potential (ΔΨ)
Mitochondrial transmembrane potential was investigated
using a fluorochrome, JC-1 dye (Biotium). JC-1 (5,5’,6,6’-
tetrachloro-1,1’,3,3’ tetra ethyl benzimidazolyl carbo
cyanine iodide) dye exhibits potential-dependent accumu-
lation of red fluorescent J-aggregates in energized mito-
chondria. JC-1 exists as a green fluorescent (535 nm)
monomer and also accumulates as J-aggregates (595 nm)
in the active mitochondria, which stain red. Consequently,
healthy cells will exhibit high red/green fluorescence
intensity ratio. In apoptotic cells, mitochondrial depolari-
zation is indicated by a decrease in the red/green fluores-
cence intensity ratio. Therefore this fluorescence emission
shift from green (~529 nm) to red (~590 nm) is indicative
of mitochondrial depolarization occurring during apopto-
sis. After 48 h of 12.5 µM and 25 µM of HHQ treatment,
the cells were incubated with 1X JC-1 dye at 37 °C for
15 min followed by washes with assay buffer. The red
fluorescence (excitation 550 nm, emission 600 nm) and
green fluorescence (excitation 485 nm, emission 535 nm)
were measured using fluorescence Thermo Scientific
Varioskan Flash Multimode plate reader. The ratio of red
fluorescence to green fluorescence was determined in JC-1
stained cells. The relative mitochondrial membrane
potential (%) was expressed as a percentage relative to the
untreated control cells.
Immunocytostaining
In order to find out the modulation of test proteins by
HHQ through PPARg, the test protein were immunos-
tained. For immunostaining, cells were plated on glass
coverslips in a 12-well plate (104 cells/coverslip). The cells
were allowed to attach for 24 h and then exposed to
12.5 µM and 25 µM of HHQ for 48 h. At the end of treat-
ment cells were washed with cold PBS three times and
then fixed with pre-chilled methanol: acetone mixture
(1:1) for 10 min at room temperature. Fixed cells were
washed twice with PBS, permeabilized with 0.32% Triton
X-100 in PBS (PBST) for 10 min and blocked with 2%
bovine serum albumin (BSA) in PBS for 30 min. The cells
were then probed with anti-PGK1 (1:250; Abcam,
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Cambridge, UK), anti-PKM2 (1:250; Abcam, Cambridge,
UK), antibodies for overnight at 4°C. After primary anti-
body incubation the cells were washed thrice with 0.1%
PBST, and then incubated with secondary antibodies
(Alexa-594-conjugated goat anti-rabbit and Alexa 488-
conjugated goat anti-mouse, (Molecular Probes, Eugene,
OR) for 1 h at room temperature followed by 3 times
washing with 0.1% PBST and then once with PBS. The
coverslips were then mounted with ProLong+® Gold anti-
fade reagent (Molecular Probes, Inc.) and observed under
a microscope (Axiovert 200M; Carl Zeiss, Thornwood,
NY). The experiment was carried out in duplicate in
three independent experiments. The images were ana-
lyzed with Axio Vision software (version 4.4, Carl Zeiss).
Western blot analysis
Expression level of indicated proteins was examined by
Western blotting. The control and treated cells were lysed
in RIPA lysis buffer (25 mM Tris-HCl (pH 7.6), 1% NP-40,
1% sodium deoxycholate, 150 mM NaCl, 0.1% SDS) com-
plemented with complete protease inhibitors (Roche) for
15 min on ice followed by centrifugation at 14,000 g for
15 min at 4 °C. The protein concentration was determined
using BCA reagents (Pierce, Rockford, IL, USA). Protein
lysate (20 µg) was resolved in 10% in SDS-polyacrylamide
gel under standard denaturing conditions according to
Laemmli’s method (1970) followed by transfer onto polyvi-
nylidene difluoride membranes using a Trans-Blot SD
(Bio-Rad, Lewes, E. Sussex, UK.) semi-dry electroblotter
for 30 min at 20 V. Subsequently, the membranes were
blocked for 45 min at room temperature with 2% bovine
serum albumin in 0.1% PBST. The membranes were then
probed with anti-PGK1 (1:1000; Abcam, Cambridge, UK),
anti-PKM2 (1:500, Abcam), anti-caspase-8 (1:1000; Cell
Signaling, Boston, MA, USA), Anti-Bax (1:1000; Cell
Signaling) and anti-b-actin (1:20,000; Abcam) at 4°C
overnight followed by three washes for 5 min each with
0.1% PBST. The membranes were then incubated with
horseradish peroxidase conjugated secondary antibody
(1:20,000; Abcam) for 45 min at RT and washed thrice for
5 min each with 0.1% PBST followed by chemiluminescent
detection using Luminescent Image Analyzer equipped
with charge-coupled device camera (LAS-4000 Ver. 2.1;
Fuji Film, Tokyo, Japan).
Data analysis
The captured images for ROS assay and immunostaining
were analyzed using AxioVision software (version 4.4; Carl
Zeiss). The analysis determined the overall density of ROS,
PGK1 and PKM2 immunoreactivity in 5-8 randomly
selected fields in each slide. The mean intensity of ROS,
PGK1, and PKM2 immunoreactivity in control and
treated cells were evaluated and presented as a histo-
gram. Similarly the Relative Optical Density (%) for
immunoreactive bands in western blotting for PGK1,
PKM2 and Caspase-8 were analyzed using Image J software
(National Institutes of Health).
Statistical analysis
The quantitative data are representative of three indepen-
dent experiments done in triplicates and expressed as
mean ± SEM. Statistical analysis was performed using ana-
lysis of variance (one way analysis of variance) followed by
Bonferroni’s on test to determine differences in mean and
p < 0.05 was considered as statistically significant.
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